The pathophysiology of acute graft-versus-host disease

被引:171
作者
Ferrara, JLM [1 ]
Cooke, KR [1 ]
Teshima, T [1 ]
机构
[1] Univ Michigan, Ctr Canc, Bone Marrow Transplant Program, Ann Arbor, MI 48109 USA
关键词
bone marrow transplantation; graft-versus-host disease; cytokines; TNF-alpha; IL-1; beta;
D O I
10.1007/BF02983793
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pathophysiology of acute graft-versus-host disease (GVHD) is a complex process that can be conceptualized in three phases. In the first phase, high-dose chemoradiotherapy causes damage to host tissues, including a self-limited burst of inflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin 1. These cytokines activate host antigen-presenting cells (APCs). In the second phase, donor T-cells recognize alloantigens on host APCs. These activated T-cells then proliferate, differentiate into effector cells, and secrete cytokines, particularly interferon (IFN)-gamma. In the third phase, target cells undergo apoptosis mediated by cellular effectors (eg, donor cytotoxic T-lymphocytes) and inflammatory cytokines such as TNF-alpha. TNF-alpha. secretion is amplified by stimuli such as endotoxin that leaks across damaged gastrointestinal mucosa injured by the chemoradiotherapy in the first phase. TNF-alpha and IFN-gamma cause further injury to gastrointestinal epithelium, causing more endotoxin leakage and establishing a positive inflammatory feedback loop. These events are examined in detail in the following review. Int J Hematol. 2003;78:181-187. (C)2003 The Japanese Society of Hematology.
引用
收藏
页码:181 / 187
页数:7
相关论文
共 114 条
[1]   INTERLEUKIN-1 IS A CRITICAL EFFECTOR MOLECULE DURING CYTOKINE DYSREGULATION IN GRAFT-VERSUS-HOST DISEASE TO MINOR HISTOCOMPATIBILITY ANTIGENS [J].
ABHYANKAR, S ;
GILLILAND, DG ;
FERRARA, JLM .
TRANSPLANTATION, 1993, 56 (06) :1518-1523
[2]   Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation [J].
Antin, JH ;
Weisdorf, D ;
Neuberg, D ;
Nicklow, R ;
Clouthier, S ;
Lee, SJ ;
Alyea, E ;
McGarigle, C ;
Blazar, BR ;
Sonis, S ;
Soiffer, RJ ;
Ferrara, JLM .
BLOOD, 2002, 100 (10) :3479-3483
[3]  
AUTRAN B, 1991, BLOOD, V77, P2237
[4]   Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function [J].
Baker, MB ;
Riley, RL ;
Podack, ER ;
Levy, RB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (04) :1366-1371
[5]   The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice [J].
Baker, MB ;
Altman, NH ;
Podack, ER ;
Levy, RB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2645-2656
[6]  
BAYSTON K, 1991, BONE MARROW TRANSPL, V8, P426
[7]  
BEELEN DW, 1992, BLOOD, V80, P2668
[8]   Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies:: Final results and long-term follow-up of an open-label prospective randomized trial [J].
Beelen, DW ;
Elmaagacli, A ;
Müller, KD ;
Hirche, H ;
Schaefer, UW .
BLOOD, 1999, 93 (10) :3267-3275
[9]   Altered T-cell receptor+CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-β-treated alloreactive T cells that do not induce graft-versus-host disease [J].
Boussiotis, VA ;
Chen, ZM ;
Zeller, JC ;
Murphy, WJ ;
Berezovskaya, A ;
Narula, S ;
Roncarolo, MG ;
Blazar, BR .
BLOOD, 2001, 97 (02) :565-571
[10]   Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease [J].
Braun, MY ;
Lowin, B ;
French, L ;
AchaOrbea, H ;
Tschopp, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (02) :657-661